The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 787,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Cell & gene therapy in pharma: corneal endothelial cell culturingBuy the report here.

Smarter leaders trust GlobalData

According to GlobalData’s Technology Foresights, which uses over 668,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.

Corneal endothelial cell culturing is a key innovation area in cell & gene therapy

Culturing corneal endothelial cells is an essential technique in regenerative medicine and ophthalmology research, as it allows for the expansion of these cells for various purposes, including corneal tissue engineering and transplantation. Corneal endothelial cells are responsible for maintaining the clarity of the cornea by regulating fluid balance. Culturing corneal endothelial cells requires adherence to strict aseptic techniques to prevent contamination. Additionally, maintaining the appropriate culture conditions, growth factors, and medium composition is essential for successful cell expansion and experimentation.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 60+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of corneal endothelial cell culturing.

Key players in corneal endothelial cell culturing – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.   

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.  

Patent volumes related to corneal endothelial cell culturing

Company Total patents (2021 - 2023) Premium intelligence on the world's largest companies
Astellas Pharma 264 Unlock Company Profile
Sumitomo Chemical 166 Unlock Company Profile
Riken 133 Unlock Company Profile
Lineage Cell Therapeutics 124 Unlock Company Profile
Senju Pharmaceutical 66 Unlock Company Profile
Healios 51 Unlock Company Profile
Novartis 38 Unlock Company Profile
Centre National de la Recherche Scientifique 28 Unlock Company Profile
Mayo Clinic 22 Unlock Company Profile
Ecole Normale Supérieure de Paris 21 Unlock Company Profile
Children's Medical Center 19 Unlock Company Profile
ActualEyes 19 Unlock Company Profile
Neurotech USA 18 Unlock Company Profile
Pfizer 16 Unlock Company Profile
Alnylam Pharmaceuticals 15 Unlock Company Profile
CorneaGen 13 Unlock Company Profile
Mitsubishi Chemical Group 13 Unlock Company Profile
Doshisha 13 Unlock Company Profile
Avita International 13 Unlock Company Profile
Fujifilm 13 Unlock Company Profile
YouHealth Eyetech 12 Unlock Company Profile
Acro Biomedical 11 Unlock Company Profile
Japan Chemical Research & Industries 10 Unlock Company Profile
U.S. Department of Veterans Affairs 10 Unlock Company Profile
Mackay Memorial Hospital 9 Unlock Company Profile
TreeFrog Therapeutics 9 Unlock Company Profile
Pandorum Technologies 8 Unlock Company Profile
Kala Pharmaceuticals 8 Unlock Company Profile
Daiichi Sankyo 7 Unlock Company Profile
Avellino Lab USA 7 Unlock Company Profile
HLB 7 Unlock Company Profile
International Stem Cell 7 Unlock Company Profile
Youvision Biotech 6 Unlock Company Profile
Newcells Biotech 5 Unlock Company Profile
BioLamina 5 Unlock Company Profile
Ministry of Trade and Industry, Singapore 5 Unlock Company Profile
Hyderabad Eye Research Foundation 5 Unlock Company Profile
REGENERATIVE RESEARCH FOUNDATION 4 Unlock Company Profile
Yang Jing 4 Unlock Company Profile
Massachusetts Eye and Ear Infirmary 3 Unlock Company Profile
Buddhist Tzu Chi Medical Foundation 3 Unlock Company Profile
Helio 3 Unlock Company Profile
Max Planck Gesellschaft zur Forderung der Wissenschaften 3 Unlock Company Profile
Max Planck Society 3 Unlock Company Profile
Nitta Gelatin 3 Unlock Company Profile
Artecel 2 Unlock Company Profile
Children's Hospital of Orange County 2 Unlock Company Profile
S.Biomedics 2 Unlock Company Profile
JCR Pharmaceuticals 2 Unlock Company Profile
Asan Social Welfare Foundation 2 Unlock Company Profile

Source: GlobalData Patent Analytics

Astellas Pharma is one of the leading patent filers in corneal endothelial cell culturing. Astellas Pharma is a pharmaceutical company known for its research and development efforts in various therapeutic areas, including ophthalmology. The company investigates a variety of ocular cell types, including photoreceptor cells, corneal endothelial cells, and retinal ganglion cells. A clinically advanced program underway by the company is examining the use of retinal pigmented epithelium cells to improve vision in patients with age-related macular degeneration. Sumitomo Chemical and Riken are some of the other key patent filers in corneal endothelial cell culturing.

In terms of application diversity, Acro Biomedical leads the pack, while Daiichi Sankyo and Pandorum Technologies stood in the second and third positions, respectively. By means of geographic reach, Astellas Pharma held the top position, followed by Novartis and Sumitomo Chemical.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.